Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Malignant Lymphoma

  Free Subscription


02.11.2026

1 Blood
6 Br J Haematol
2 Haematologica
1 Lancet Oncol
3 Leuk Lymphoma


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Blood

  1. LANE AA, Luskin MR, Keating J, LeBoeuf NR, et al
    Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm.
    Blood. 2026;148:2229-2238.
    PubMed         Abstract available


    Br J Haematol

  2. JAWOREK CP, Borchmann P, von Tresckow B
    Condensed 3-day BrECADD and time toxicity: Several roads to cure in advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2026 Oct 29. doi: 10.1111/bjh.70918.
    PubMed        

  3. PANOZZO B, Robinson S, Westerman DA, Dowling MR, et al
    Reply to 'Interpreting day-7 CAR-T expansion in large B-cell lymphoma: Timing and baseline risk adjustment'.
    Br J Haematol. 2026 Oct 29. doi: 10.1111/bjh.70919.
    PubMed        

  4. YANG J
    Interpreting day-7 CAR-T expansion in large B-cell lymphoma: Timing and baseline risk adjustment.
    Br J Haematol. 2026 Oct 27. doi: 10.1111/bjh.70920.
    PubMed        

  5. PICARDI M, Vincenzi A, Pane F
    Brentuximab vedotin-containing regimen time toxicity for front-line therapy of advanced-stage classical Hodgkin lymphoma in young adults and adults: Real-life comparison between condensed BrECADD versus traditional Bv + AVD.
    Br J Haematol. 2026 Oct 26. doi: 10.1111/bjh.70917.
    PubMed        

  6. WEE K, Zhao EJ, Clemente-Jones C, Deyell RJ, et al
    Whole-genome and transcriptome analysis in relapsed/refractory non-Hodgkin lymphoma: Results from a multicentre precision oncology cohort.
    Br J Haematol. 2026 Oct 23. doi: 10.1111/bjh.70907.
    PubMed         Abstract available

  7. SHUMILOV E, Ziepert M, Friedrichs B, Ghandili S, et al
    Ibrutinib and standard immunochemotherapy in younger, high-risk patients with diffuse large B-cell lymphoma: A phase II study of GLA.
    Br J Haematol. 2026 Oct 23. doi: 10.1111/bjh.70902.
    PubMed         Abstract available


    Haematologica

  8. YAN M, Parikh SA, De Melo MKS, Hampel PJ, et al
    Immunogenomic characterization of classic Hodgkin lymphoma variant of Richter transformation reveals shared biology with de novo classic Hodgkin lymphoma.
    Haematologica. 2026 Oct 29. doi: 10.3324/haematol.2026.301780.
    PubMed         Abstract available

  9. BEWARDER M, Bewarder Y, Neumann F, Baumann C, et al
    Beta-blocker use and survival in diffuse large B-cell lymphoma: a post hoc analysis of the RICOVER-60 trial.
    Haematologica. 2026 Oct 29. doi: 10.3324/haematol.2026.301369.
    PubMed         Abstract available


    Lancet Oncol

  10. BORCHMANN P, van Meerten T, Iacoboni G, Bories P, et al
    Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 st
    Lancet Oncol. 2026;27:1403-1419.
    PubMed         Abstract available


    Leuk Lymphoma

  11. KOPEC K, Falek M, Piotrowska J, Lawski A, et al
    Lower baseline eosinophil counts are associated with inferior survival in Mantle cell lymphoma.
    Leuk Lymphoma. 2026 Oct 29:1-9. doi: 10.1080/10428194.2026.2750499.
    PubMed         Abstract available

  12. COLRAT F, Despas F, Branchoux S, Kone S, et al
    Care pathway of patients with second-line large B-cell lymphoma treated with CAR T-cell therapies in France.
    Leuk Lymphoma. 2026 Oct 28:1-10. doi: 10.1080/10428194.2026.2752787.
    PubMed         Abstract available

  13. CHEN W, Yuan F, Xu J, Peng S, et al
    Zanubrutinib with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory non-germinal center B-cell lymphoma.
    Leuk Lymphoma. 2026 Oct 28:1-8. doi: 10.1080/10428194.2026.2735668.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum